Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain.

Nomura M, Inoue K, Matsushita S, Takahari D, Kondoh C, Shitara K, Ura T, Hayashi K, Kojima H, Kamata M, Tatematsu M, Hosoda R, Sawada S, Oka H, Muro K.

Clin J Pain. 2013 Jun;29(6):487-91. doi: 10.1097/AJP.0b013e318266f6a5.

PMID:
23328324
2.

A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.

Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL.

Cancer. 2001 Dec 15;92(12):3056-61.

PMID:
11753984
3.

Transdermal fentanyl in cachectic cancer patients.

Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E.

Pain. 2009 Jul;144(1-2):218-22. doi: 10.1016/j.pain.2009.04.012. Epub 2009 May 12.

PMID:
19442446
4.

Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain.

Miyazaki T, Hanaoka K, Namiki A, Ogawa S, Kitajima T, Hosokawa T, Ishida T, Nogami S, Mashimo S.

Clin Drug Investig. 2008;28(5):313-25.

PMID:
18407717
5.

Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain.

Samala RV, Bloise R, Davis MP.

J Pain Symptom Manage. 2014 Jul;48(1):132-6. doi: 10.1016/j.jpainsymman.2013.09.001. Epub 2013 Dec 2.

PMID:
24291296
6.

Transdermal fentanyl in postoperative pain.

Lehmann LJ, DeSio JM, Radvany T, Bikhazi GB.

Reg Anesth. 1997 Jan-Feb;22(1):24-8.

PMID:
9010943
7.

A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain.

Kornick CA, Santiago-Palma J, Schulman G, O'Brien PC, Weigand S, Payne R, Manfredi PL.

Cancer. 2003 Jun 15;97(12):3121-4.

8.

Pharmacokinetics of fentanyl following intravenous and transdermal administration in horses.

Maxwell LK, Thomasy SM, Slovis N, Kollias-Baker C.

Equine Vet J. 2003 Jul;35(5):484-90.

PMID:
12875327
9.

From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.

Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L.

Anticancer Res. 2001 May-Jun;21(3C):2225-30.

PMID:
11501851
10.

A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.

Mitra F, Chowdhury S, Shelley M, Williams G.

Pain Med. 2013 Jan;14(1):75-83. doi: 10.1111/pme.12011.

PMID:
23320402
11.

Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.

Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, Pinguet F.

Ther Drug Monit. 2005 Aug;27(4):491-8.

PMID:
16044107
12.

Disposition of transdermally administered fentanyl in dogs.

Kyles AE, Papich M, Hardie EM.

Am J Vet Res. 1996 May;57(5):715-9.

PMID:
8723888
13.

[Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].

Yamazaki K, Fujio N, Ishikawa N, Watanabe H, Kameyama M.

Gan To Kagaku Ryoho. 2012 Mar;39(3):405-8. Japanese.

PMID:
22421768
14.

Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.

Hoya Y, Okamoto T, Yanaga K.

Support Care Cancer. 2010 Jun;18(6):761-4. doi: 10.1007/s00520-010-0869-y. Epub 2010 Mar 31.

PMID:
20354734
15.

Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.

Nomura M, Kamata M, Kojima H, Hayashi K, Kozai M, Sawada S.

Support Care Cancer. 2011 May;19(5):691-5. doi: 10.1007/s00520-010-0890-1. Epub 2010 Jun 13.

PMID:
20549247
16.

Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.

Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J.

Drug Metab Pharmacokinet. 2012;27(4):414-21. Epub 2012 Jan 24.

17.

Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.

Tawfik MO, Bryuzgin V, Kourteva G; FEN-INT-20 Study Group..

Curr Med Res Opin. 2004 Mar;20(3):259-67.

PMID:
15025835
18.

Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.

Carroll GL, Hooper RN, Boothe DM, Hartsfield SM, Randoll LA.

Am J Vet Res. 1999 Aug;60(8):986-91.

PMID:
10451210
19.

Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.

Benítez-Rosario MA, Feria M, Salinas-Martín A, Martínez-Castillo LP, Martín-Ortega JJ.

Cancer. 2004 Dec 15;101(12):2866-73.

20.

Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats.

Lee DD, Papich MG, Hardie EM.

Am J Vet Res. 2000 Jun;61(6):672-7.

PMID:
10850844

Supplemental Content

Support Center